-
Histopathology May 1997The diagnosis of malignant mesothelioma can pose several problems to the surgical pathologist. First, the morphological appearances of the tumour are known to be diverse... (Review)
Review
The diagnosis of malignant mesothelioma can pose several problems to the surgical pathologist. First, the morphological appearances of the tumour are known to be diverse with mimicry of a range of both reactive and neoplastic conditions. Second, due to the relative inaccessibility of the serosa, biopsy material is often scanty and fragmentary, producing a plethora of interpretive ambiguities. Third, adjunct techniques such as mucin histochemistry and immunohistochemistry, whilst useful in excluding malignant mesothelioma have little role in confirming the diagnosis. The accurate diagnosis of diffuse malignant mesothelioma is important for two reasons: (1) In relation to prognosis as it has an almost invariable fatal outcome, which contrasts with the other mesothelial neoplasms such as the benign adenomatoid tumour and the borderline malignant tumours, namely the well-differentiated papillary mesothelioma and multicystic mesothelioma; (2) In relation to occupational-related compensation claims following asbestos exposure. This review summarizes the aetiology of asbestos-induced neoplasia, possible mechanisms of tumour development and highlights potential diagnostic pitfalls.
Topics: Asbestos; Diagnosis, Differential; Heart Neoplasms; Histocytochemistry; Humans; Male; Mesothelioma; Pericardium; Peritoneal Neoplasms; Pleural Neoplasms; Testicular Neoplasms
PubMed: 9181361
DOI: 10.1046/j.1365-2559.1997.5460776.x -
Ryoikibetsu Shokogun Shirizu 1996
Review
Topics: Diagnosis, Differential; Heart Neoplasms; Humans; Mesothelioma; Pericardium
PubMed: 9047851
DOI: No ID Found -
The Annals of Thoracic Surgery Nov 2018Primary pericardial mesothelioma represents less than 1% of all malignant mesotheliomas. These tumors are very rare, difficult to diagnose, and have a poor response to...
Primary pericardial mesothelioma represents less than 1% of all malignant mesotheliomas. These tumors are very rare, difficult to diagnose, and have a poor response to established treatments. Common clinical presentations include constrictive symptoms, cardiac tamponade, and cardiac failure. Surgical resection can be curative in early stages and for localized tumors, and pericardiectomy and chemotherapy are often used as palliative approaches. We present the case of a 54-year-old woman who has so far survived 4 years after a primary resection of a pericardial mesothelioma and was referred with myocardial and aortopulmonary window recurrences for further treatment.
Topics: Biopsy, Needle; Female; Follow-Up Studies; Heart Neoplasms; Humans; Immunohistochemistry; Lung Neoplasms; Magnetic Resonance Imaging, Cine; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Myocardium; Neoplasm Recurrence, Local; Pericardial Effusion; Pericardiectomy; Pericardium; Reoperation; Risk Assessment; Thoracotomy; Tomography, X-Ray Computed; Treatment Outcome
PubMed: 29792828
DOI: 10.1016/j.athoracsur.2018.04.057 -
The Annals of Thoracic Surgery Dec 2018
Topics: Heart Failure; Heart Neoplasms; Humans; Male; Mesothelioma; Middle Aged; Pericardium
PubMed: 29966594
DOI: 10.1016/j.athoracsur.2018.05.077 -
Acta Oncologica (Stockholm, Sweden) May 2021
Topics: Heart Neoplasms; Humans; Immune Checkpoint Inhibitors; Mesothelioma; Mesothelioma, Malignant; Thymus Neoplasms
PubMed: 33620252
DOI: 10.1080/0284186X.2021.1887515 -
International Journal of Molecular... Mar 2020Malignant mesothelioma is an infrequent tumor that initiates from the mesothelial cells lining of body cavities. The great majority of mesotheliomas originate in the... (Review)
Review
Malignant mesothelioma is an infrequent tumor that initiates from the mesothelial cells lining of body cavities. The great majority of mesotheliomas originate in the pleural cavity, while the remaining cases initiate in the peritoneal cavity, in the pericardial cavity or on the tunica vaginalis. Usually, mesotheliomas grow in a diffuse pattern and tend to enclose and compress the organs in the various body cavities. Mesothelioma incidence is increasing worldwide and still today, the prognosis is very poor, with a reported median survival of approximately one year from presentation. Thus, the development of alternative and more effective therapies is currently an urgent requirement. The aim of this review article was to describe recent findings about the anti-cancer activity of curcumin and some of its derivatives on mesotheliomas. The potential clinical implications of these findings are discussed.
Topics: Antineoplastic Agents; Curcumin; Humans; Mesothelioma, Malignant; Phytochemicals; Pleura; Pleural Neoplasms; Prognosis
PubMed: 32155978
DOI: 10.3390/ijms21051839 -
International Journal of Colorectal... Jan 2015Malignant mesothelioma is a rare, insidious, and aggressive tumor arising from the mesothelial surface of pleural and peritoneal cavities, the pericardium, or the tunica... (Review)
Review
BACKGROUND
Malignant mesothelioma is a rare, insidious, and aggressive tumor arising from the mesothelial surface of pleural and peritoneal cavities, the pericardium, or the tunica vaginalis, with an increasing incidence worldwide, high misdiagnosis rate, and overall negative prognosis. A total of 20% of all cases is peritoneum in origin.
METHODS
The present study is a review of literatures focusing on the advances in epidemiology, clinical presentations, radiological features, diagnosis, misdiagnosis, management, and prognostic factors of malignant peritoneal mesothelioma (MPM) occurred in the past decades.
RESULTS
Asbestos, SV40, and radiation exposures have been demonstrated to be correlated with the pathogenesis of MPM. The main presentations are abdominal distension and pain. Computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography (PET) play an important role in the preoperative imaging and staging. Definitive diagnosis is made on the basis of immunohistochemistry. Prognostic factors have been identified and verified. Negative indicators include advanced age, male gender, poor performance status, non-epithelial histology, and absence of surgery. The management of MPM has evolved from single chemotherapy to multimodality treatment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), chemotherapy, radiotherapy, and immunotherapy. Promising results have been achieved after a combined treatment of CRS and HIPEC, with an elevated median survival time of 29.5-92 months and a 5-year survival rate of 39-63%.
CONCLUSIONS
CRS and HIPEC represent the standard treatment strategy for selected patients with MPM, and patients with unresectable tumors can benefit from the combined treatment of chemotherapy, radiotherapy, and immunotherapy.
Topics: Diagnosis, Differential; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Peritoneal Neoplasms; Prognosis
PubMed: 25331029
DOI: 10.1007/s00384-014-2029-1 -
American Heart Journal Dec 1986
Topics: Cardiac Catheterization; Diagnostic Errors; Echocardiography; Heart Neoplasms; Humans; Mesothelioma; Pericardium
PubMed: 3788794
DOI: 10.1016/0002-8703(86)90390-x -
Danish Medical Bulletin Aug 1974
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Diagnosis, Differential; Female; Heart Diseases; Heart Neoplasms; Humans; Infant; Male; Mesothelioma; Middle Aged; Pericardial Effusion; Pericarditis; Pericardium
PubMed: 4853774
DOI: No ID Found -
Histopathology Mar 2024Mesothelioma is a rare malignancy of the serosal membranes that is commonly related to exposure to asbestos. Despite extensive research and clinical trials, prognosis to... (Review)
Review
AIMS
Mesothelioma is a rare malignancy of the serosal membranes that is commonly related to exposure to asbestos. Despite extensive research and clinical trials, prognosis to date remains poor. Consistent, comprehensive and reproducible pathology reporting form the basis of all future interventions for an individual patient, but also ensures that meaningful data are collected to identify predictive and prognostic markers.
METHODS AND RESULTS
This article details the International Collaboration on Cancer Reporting (ICCR) process and the development of the international consensus mesothelioma reporting data set. It describes the 'core' and 'non-core' elements to be included in pathology reports for mesothelioma of all sites, inclusive of clinical, macroscopic, microscopic and ancillary testing considerations. An international expert panel consisting of pathologists and a medical oncologist produced a set of data items for biopsy and resection specimens based on a critical review and discussion of current evidence, and in light of the changes in the 2021 WHO Classification of Tumours. The commentary focuses particularly upon new entities such as mesothelioma in situ and provides background on relevant and essential ancillary testing as well as implementation of the new requirement for tumour grading.
CONCLUSION
We recommend widespread and consistent implementation of this data set, which will facilitate accurate reporting and enhance the consistency of data collection, improve the comparison of epidemiological data, support retrospective research and ultimately help to improve clinical outcomes. To this end, all data sets are freely available worldwide on the ICCR website (www.iccr-cancer.org/data-sets).
Topics: Humans; Peritoneum; Pleura; Retrospective Studies; Mesothelioma; Mesothelioma, Malignant; Pericardium; Pathology, Clinical
PubMed: 38044849
DOI: 10.1111/his.15106